In patients with adult-onset dermatomyositis (DM), negative antinuclear antibody (ANA) is associated with increased likelihood of developing malignancy within 3 years of DM diagnosis, according to a recent retrospective cohort study of patients. Therefore, particularly close follow-up and frequent malignancy screening may be warranted in ANA-negative individuals with DM. Researchers compared the incidence of amyopathic disease, risk of malignancy, and clinical findings in ANA-positive and ANA-negative patients with adult-onset DM. They found:
- Of 231 patients, 140 (61%) were ANA-positive and 91 (39%) were ANA-negative.
- Compared to ANA-negative patients, ANA-positive patients had a lower frequency of dysphagia (15% vs 26%) and heliotrope rash (38% vs 53%).
- 54 patients (23%) developed malignancy within 3 years of DM diagnosis.
- 11% of ANA-positive patients developed malignancy vs 43% of ANA-negative patients.
- There was a strong association between ANA positivity and lower likelihood of malignancy in multivariable analysis (OR: 0.16).
- Conversely, ANA positivity was not associated with amyopathic disease (OR: 0.94).
Hoesly PM, Sluzevich JC, Jambusaria-Pahlajani A, Lesser ER, Heckman MG, Abril A. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis. [Published online ahead of print November 17, 2018]. J Am Acad Dermatol. doi:10.1016/j.jaad.2018.11.023.
This Week's Must Reads
Must Reads in Rare Diseases
Risk Prediction of In-Hospital Mortality for SJS/TEN, JAMA Dermatol; ePub 2019 Mar 6; Noe, et al